Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

NCT00811733 ·Status: COMPLETED ·Phase: PHASE2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT04840602 ·Status: RECRUITING ·Phase: PHASE2

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142116 ·Status: COMPLETED ·Phase: PHASE2

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

NCT02658968 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

NCT01796171 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

NCT02371148 ·Status: COMPLETED ·Phase: PHASE2

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00004889 ·Status: COMPLETED ·Phase: PHASE2

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

NCT00060346 ·Status: TERMINATED ·Phase: PHASE2

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

NCT00324779 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

NCT05099471 ·Status: RECRUITING ·Phase: PHASE2

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

NCT03620903 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

NCT00010192 ·Status: COMPLETED ·Phase: PHASE1

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

NCT07169565 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

NCT00667329 ·Status: COMPLETED ·Phase: PHASE1

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

NCT01779167 ·Status: TERMINATED ·Phase: PHASE2

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00060294 ·Status: TERMINATED ·Phase: PHASE1

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

NCT00765245 ·Status: COMPLETED ·Phase: PHASE2

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

NCT00142168 ·Status: TERMINATED ·Phase: PHASE2

Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma

NCT00347971 ·Status: COMPLETED ·Phase: PHASE1

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

NCT02677324 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

NCT01788020 ·Status: COMPLETED ·Phase: PHASE3

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT01741792 ·Status: COMPLETED ·Phase: PHASE2

Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy

NCT00003716 ·Status: COMPLETED ·Phase: PHASE2

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

NCT00460109 ·Status: COMPLETED ·Phase: PHASE2

Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

NCT02281279 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2